All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Treatment of leukemia with transplantation of allogeneic bone marrow or stem cells from the peripheral blood is limited by the poor number of HLA-matched related donors. The purpose of this study was to conduct a retrospective analysis of outcomes in patients with Acute Lymphoid Leukemia (n=185), Acute Myeloid Leukemia (n=300) or Myelodysplastic Syndrome (n=97), who either received a transplant from a cord-blood donor (n=140), a HLA-matched unrelated donor (n=344) or from a HLA-mismatched unrelated donor (n=98).
Dr Filippo Milano and his colleagues from the Fred Hutchinson Cancer Research Centre, Seattle, USA, also analyzed if there was a difference in the relative risk of deaths and relapse between the cord-blood group and the other two unrelated donor groups with respect to numerous outcomes according to presence or absence of minimal residual disease (MRD) before transplantation. They published their data in the New England Journal of Medicine on the 8th of September 2016.
Even though the data analyzed here focuses on a cohort of patients based on clinical priority and non-randomization, it does provide evidence and guidance regarding difficult donor choices in circumstances where a HLA-identical sibling is not available. Future studies based on randomization would determine the differences between cord-blood and unrelated-donor transplantations.
Subscribe to get the best content related to AML delivered to your inbox